ATE526977T1 - Verfahren zur inaktivierung infektioeser erreger in biologischen flüssigkeiten - Google Patents

Verfahren zur inaktivierung infektioeser erreger in biologischen flüssigkeiten

Info

Publication number
ATE526977T1
ATE526977T1 AT00988518T AT00988518T ATE526977T1 AT E526977 T1 ATE526977 T1 AT E526977T1 AT 00988518 T AT00988518 T AT 00988518T AT 00988518 T AT00988518 T AT 00988518T AT E526977 T1 ATE526977 T1 AT E526977T1
Authority
AT
Austria
Prior art keywords
plasma
animal
solvent system
inactivation
infectious pathogens
Prior art date
Application number
AT00988518T
Other languages
English (en)
Inventor
Bill Cham
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE526977T1 publication Critical patent/ATE526977T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00988518T 1999-12-23 2000-12-28 Verfahren zur inaktivierung infektioeser erreger in biologischen flüssigkeiten ATE526977T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ4866A AUPQ486699A0 (en) 1999-12-23 1999-12-23 A method of treating infectious diseases
PCT/AU2000/001603 WO2001045718A1 (en) 1999-12-23 2000-12-28 A method of treating infectious diseases

Publications (1)

Publication Number Publication Date
ATE526977T1 true ATE526977T1 (de) 2011-10-15

Family

ID=3819005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00988518T ATE526977T1 (de) 1999-12-23 2000-12-28 Verfahren zur inaktivierung infektioeser erreger in biologischen flüssigkeiten

Country Status (11)

Country Link
EP (1) EP1242099B1 (de)
JP (1) JP2003522740A (de)
KR (1) KR20020084079A (de)
AT (1) ATE526977T1 (de)
AU (2) AUPQ486699A0 (de)
BR (1) BR0016685A (de)
CA (1) CA2395125A1 (de)
ES (1) ES2372745T3 (de)
RU (1) RU2002119578A (de)
WO (1) WO2001045718A1 (de)
ZA (1) ZA200205327B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407662B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US7407663B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US7033500B2 (en) 2001-06-25 2006-04-25 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
PL1567188T3 (pl) * 2003-06-20 2012-12-31 Lilly Co Eli Zmodyfikowane cząstki wirusa o właściwościach immunogennych i zmniejszonej zawartości lipidów użyteczne do leczenia i profilaktyki chorób zakaźnych
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
JP2007527387A (ja) 2003-07-03 2007-09-27 リピッド サイエンシーズ，インコーポレイテッド 脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置
WO2019104237A1 (en) 2017-11-22 2019-05-31 Hdl Therapeutics, Inc. Systems and methods for priming fluid circuits of a plasma processing system
EP3731814A4 (de) 2017-12-28 2021-09-29 HDL Therapeutics, Inc. Verfahren zur konservierung und verabreichung von aus menschlichem plasma extrahiertem prä-beta-lipoprotein hoher dichte

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1538322A (fr) * 1966-11-21 1968-09-06 Rhone Poulenc Sa Procédé de préparation d'une suspension virale inactivée
US4591505A (en) 1982-04-14 1986-05-27 New York Blood Center, Inc. Process for inactivating hepatitis B virus
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4895558A (en) 1985-07-15 1990-01-23 University Of Queensland Autologous plasma delipidation using a continuous flow system
ATE69383T1 (de) * 1985-11-22 1991-11-15 Schweiz Serum & Impfinst Verfahren zur herstellung eines tollwutimpfstoffes und nach diesem verfahren erhaltener impfstoff.
US5484396A (en) 1988-11-17 1996-01-16 Naficy; Sadeque S. Method and device for treatment of HIV infections and AIDS
USRE37584E1 (en) 1993-07-30 2002-03-19 Aruba International Pty Ltd Solvent extraction methods for delipidating plasma

Also Published As

Publication number Publication date
EP1242099A4 (de) 2005-01-05
EP1242099A1 (de) 2002-09-25
AUPQ486699A0 (en) 2000-02-03
EP1242099B1 (de) 2011-10-05
JP2003522740A (ja) 2003-07-29
RU2002119578A (ru) 2004-01-27
AU783214B2 (en) 2005-10-06
AU2493001A (en) 2001-07-03
WO2001045718A1 (en) 2001-06-28
CA2395125A1 (en) 2001-06-28
ZA200205327B (en) 2004-04-05
BR0016685A (pt) 2003-02-25
ES2372745T3 (es) 2012-01-26
KR20020084079A (ko) 2002-11-04

Similar Documents

Publication Publication Date Title
AU9058091A (en) Preparation of nucleic acid samples
DE69535482D1 (de) Verfahren und anordnung von beuteln zur konzentrierung weisser zellen
ATE248011T1 (de) System und methode zur trennung von erythrocyten
DE3382723D1 (de) Adsorbens und Verfahren zu dessen Herstellung.
EP1242099A4 (de) Methode zur behandlung von infektionskrankheiten
BR0212469A (pt) Método para multiplicação de vìrus em cultura de célula
BRPI0416898A (pt) dispositivos de filtragem de fluxo tangencial e métodos para o enriquecimento de células-tronco
EP0830058A4 (de) Die beseitigung von sauerstoff beinhaltendes verfahren zur verlängerung der nutzbaren bevorratungszeit von gekühlten roten blutkörperchen
MX9701183A (es) Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones.
ES2052872T3 (es) Procedimiento de inactivacion de virus.
DE60118604D1 (de) Photosensibilisator-enthaltende lagerungslösung zur inaktivierung von biologischen verunreinigungen
AU2001282265A1 (en) Screening of a novel hepatic syndrome and its uses
ATE466659T1 (de) Probenahmesystem mit phosphataseinhibitor
Loh et al. Melatonin: regulation of viral phase separation and epitranscriptomics in post-acute sequelae of COVID-19
ATE335808T1 (de) Herstellung von zellsuspensionen
SE7808686L (sv) Forfarande for pavisning av alstrare i blod
Okado et al. Safety evaluation of nuclease P1 from Penicillium citrinum
AU2284399A (en) Method for transforming plasma and implementing device
ATE361068T1 (de) Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma
ATE442434T1 (de) Verfahren zur unterdrückung einer immunsystemreaktion gegen gewebe- oder zelltransplantate
NO20025931D0 (no) Biotinderivater
GB2441944A (en) Fieldbus system with shared redundancy system
DE602005019998D1 (de) Verfahren zur sterilisation von biologischen präparaten
ATE72756T1 (de) Verfahren zur herstellung eines biologischen stoffes.
US20200337297A1 (en) System and method for carbon monoxide atmosphere stored blood components

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties